سعر بنداتريوتيد 0.2 مجم/مل فيال 5 مل للحقن تحت الجلد (غير متاح بعد) 2026

Octreotide 0.2 mg/ml in 5 ml vial for subcutaneous use; Egyptian Bendatreotid presentation marked not yet available (n/a yet).

• Symptomatic control and reduction of GH and IGF-1 in acromegaly inadequately controlled by surgery or radiotherapy; also for patients unfit/unwilling for surgery or awaiting radiotherapy effectPopulation: AdultsUK eMC / MHRA SmPC
• Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumours (e.g. carcinoid tumours with features of carcinoid syndrome)Population: AdultsUK eMC / MHRA SmPC
• Prevention of complications following pancreatic surgery; emergency management of bleeding gastro-oesophageal varices in association with specific treatment such as endoscopic sclerotherapy (per Sandostatin SmPC)Population: AdultsUK eMC / MHRA SmPC

• Very common/common: gastrointestinal effects (diarrhoea, abdominal pain, nausea, constipation, flatulence), cholelithiasis, hyperglycaemia, headache, injection-site reactions.International label, equivalent formulation · UK eMC / MHRA SmPC

• Known hypersensitivity to octreotide or any excipient.International label, equivalent formulation · UK eMC / MHRA SmPC

• Monitor for gallstones, glucose dysregulation (hypo/hyperglycaemia), thyroid function with long-term use, bradycardia, and nutritional effects (steatorrhoea, vitamin B12). GH-secreting pituitary tumours may expand — monitor visual fields.International label, equivalent formulation · UK eMC / MHRA SmPC

• CiclosporinModerateOctreotide may decrease intestinal absorption of ciclosporin; adjust dose as needed.UK eMC / MHRA SmPC
• Insulin and oral antidiabetic agentsModerateMay affect glucose regulation; antidiabetic doses may require adjustment.UK eMC / MHRA SmPC

• Limited data in pregnancy; use only if clearly needed. Women of childbearing potential should use adequate contraception during treatment (UK SmPC).International label, equivalent formulation · UK eMC / MHRA SmPC
• It is unknown whether octreotide is excreted in human milk; breast-feeding is not recommended during treatment (UK SmPC).International label, equivalent formulation · UK eMC / MHRA SmPC

English text not available for this section.